A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor.

@article{Suzdak1995ARO,
  title={A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor.},
  author={Peter D. Suzdak and Jens Jansen},
  journal={Epilepsia},
  year={1995},
  volume={36 6},
  pages={
          612-26
        }
}
We review the neurochemical and behavioral profile of the selective gamma-aminobutyric acid (GABA) uptake inhibitor, (R)-N-(4,4-di-(3-methylthien-2-yl)but-3-enyl) nipecotic acid hydrochloride [tiagabine (TGB), previously termed NNC 05-0328, NO 05-0328, and NO-328], which is currently in phase III clinical trials for epilepsy. TGB is a potent, and specific GABA uptake inhibitor. TGB lacks significant affinity for other neurotransmitter receptor binding sites and/or uptake sites. In… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 60 CITATIONS, ESTIMATED Infinity% COVERAGE

60 Citations

0246'96'01'07'13'19
Citations per Year
Semantic Scholar estimates that this publication has 60 citations based on the available data.

See our FAQ for additional information.

Similar Papers

Loading similar papers…